Medical cannabis for treatment-resistant combat PTSD

Bibliographic Data

ID15524599
AuthorsNitsa Nacasch (Clalit Health Services), Chen Avni (Clalit Health Services, corresponding author), Paz Toren (Tel Aviv University)
Year2023
Volume13
Pages1014630-1014630
Publication date2023-01-19
Peer ReviewedYes
Open AccessYes
TypeARTICLE
VenueFrontiers in Psychiatry (JOURNAL)
Journal identifiersISSN: 1664-0640 • E-ISSN: 1664-0640
PublisherFrontiers Media (PUBLISHER • CH)
DOI10.3389/fpsyt.2022.1014630
PMID36741572
OpenAlexW4317401419
LanguageEN
Citations received2
References cited36

Targeting the endocannabinoid system may have a role in the treatment of post-traumatic stress disorder (PTSD). However, few studies have examined the effectiveness of cannabis on symptoms of PTSD, and more research is needed to ascertain cannabis' effectiveness. In this retrospective naturalistic study, we followed 14 relatively mature (32-68 years of age), treatment-resistant, chronic combat post-traumatic patients who remained severely symptomatic despite treatment with many lines of conventional treatment prior to receiving medicinal cannabis. Our findings show that total sleep score, subjective sleep quality, and sleep duration significantly improved ( p p p = 0.27). The mean follow-up time was 1.1 ± 0.8 years (range of 0.5 to 3 years)

Alertness · Cannabis · Intrusiveness · Psychiatry · Cannabis and Cannabinoid Research · Medicine · Posttraumatic Stress Disorder Research · Psychology · Sleep and related disorders

Tools

Open DOIOpen Access